CN Patent

CN114569608A — Aerd/哮喘中的血栓烷受体拮抗剂

Assigned to Cumberland Pharmaceuticals Inc · Expires 2022-06-03 · 4y expired

What this patent protects

本发明涉及通过对有需要的患者给予血栓烷受体拮抗剂来治疗AERD(阿司匹林加重呼吸系统疾病)和/或哮喘的方法。

USPTO Abstract

本发明涉及通过对有需要的患者给予血栓烷受体拮抗剂来治疗AERD(阿司匹林加重呼吸系统疾病)和/或哮喘的方法。

Drugs covered by this patent

Acetadote (Acetylcysteine) · Bristol-Myers Squibb

Patent Metadata

Patent number: CN114569608A
Jurisdiction: CN
Classification: —
Expires: 2022-06-03
Drug substance claim: No
Drug product claim: No
Assignee: Cumberland Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.